StockData
Fulcrum Therapeutics, Inc. logo

Fulcrum Therapeutics, Inc. (FULC) company profile

FULCNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 8/30
$3.75+0.04 (+1.08%)

Close on Nov 17, 2026Market cap $286.12MP/E –Yield –

About Fulcrum Therapeutics

Pharmaceutical Preparations, SIC 2834

Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops small-molecule therapies to treat genetically defined rare diseases. Its lead product candidate is pociredir, an investigational oral drug engineered to stimulate fetal hemoglobin production to address the biological causes of sickle cell disease. The company also investigates drug candidates for conditions such as prostate cancer and beta-thalassemia through cellular target discovery methods. Fulcrum Therapeutics operates as a single business focused on benign hematology and genetic conditions, targeting affected patients and the hematologists who provide their clinical care.

The company maintains its corporate headquarters in Cambridge, Massachusetts, where it leases office and laboratory space. Its clinical development efforts and operational activities take place primarily in the United States, alongside regulatory outreach planned for Europe. Fulcrum Therapeutics currently has one product candidate in clinical trials and relies on external contract manufacturing organizations to produce its drug supplies as well as third-party partners to manage its clinical studies.

Summary of the business section of Fulcrum Therapeutics's latest annual report, written by StockData.

Company profile

Company

Legal name
Fulcrum Therapeutics, Inc.
Founded
2016
Headquarters
Cambridge, MA
Address
26 Landsdowne Street 02139
Phone
(617) 651-8851
Employees
55, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
Ernst & Young LLP, Boston, Massachusetts

Stock & identifiers

Ticker
FULC
Exchange
Nasdaq
IPO date
Jul 18, 2019
Shares outstanding
76M, Jul 23, 2026
Public float
$296.08M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company
SEC CIK
1680581
CUSIP
359616109
ISIN
US3596161097
FIGI
BBG00DDY1RK9
Share class FIGI
BBG00DDY1RM7
EIN
47-4839948

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Alex SapirSee Remarks, Director193,360
Alan A. MussoChief Financial Officer0
Greg TourangeauPrincipal Accounting Officer14,062
Curtis Gale OltmansChief Legal Officer10,252
Alan EzekowitzDirector10,927
James A. GeraghtyDirector90,714
Katina DortonDirector0
Robert J. GouldDirector454,864
Kate HavilandDirector–
Colin HillDirector0
Sonja BanksDirector0
Rachel K. KingDirector–
Joshua Lehrer-GraiwerDirector0

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025
Alex Sapir
$3.25M$14.93M$1.64M$15536–
FY2025
Bryan Stuart
$0$0$1.64M$15536–
FY2025
Robert JGould
$0$0$1.64M$15536–
FY2024
Alex Sapir
$1.00M-$3.26M$2.14M$6456–
FY2024
Bryan Stuart
$0$0$2.14M$6456–
FY2024
Robert JGould
$0$0$2.14M$6456–

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryOption awardsIncentive payOtherTotalvs. prior year
Alex C. Sapir
President and Chief Executive Officer
$650.00K$2.05M$411.20K$138.16K$3.25M+224%
Alan Musso
Chief Financial Officer
$478.10K$1.00M$220.00K$104.12K$1.81M+44%
Curtis Oltmans
Chief Legal Officer and Head of External Affairs
$472.20K$793.35K$217.30K–$1.48M+4%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Jul 18, 2019
Offer price
$16.00
Securities offered
4,500,000
Gross proceeds
$72.00M
Exchange
Nasdaq
First trading day
Jul 18, 2019
First-day close
$13.50-15.6%
Lock-up ends (est.)
Jan 14, 2020

“The initial public offering price is $16.00 per share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of February 17, 2026, we had 55 full-time employees, including a total of 19 employees with M.D.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?